Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.48 |
| ▸ | PPARD | Q03181 | 8/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.43 |
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023852 | 0.90 | PPARD (0.53) | PTPN1PPARDFFAR1PPARAPPARG | |
| SCHEMBL5017439 | 0.90 | PPARD (0.50) | PTPN1PPARDFFAR1PPARAPPARG | |
| SCHEMBL5017228 | 0.90 | PTPN1 (0.46) | PTPN1PPARDPPARAPPARGMCL1 | |
| SCHEMBL5017203 | 0.90 | PPARA (0.48) | PTPN1PPARDFFAR1PPARAPPARG | |
| SCHEMBL5017510 | 0.89 | PPARG (0.49) | PPARDPPARAPPARGMCL1 | |
| SCHEMBL5017515 | 0.86 | PPARD (0.49) | PTPN1PPARDFFAR1PPARAPPARG | |
| SCHEMBL5016731 | 0.82 | PPARA (0.41) | PPARDFFAR1PPARAPPARGMCL1 | |
| SCHEMBL5015457 | 0.82 | PPARD (0.51) | PTPN1PPARDFFAR1PPARAPPARG | |
| SCHEMBL5017471 | 0.82 | PPARD (0.56) | PTPN1PPARDFFAR1PPARAPPARG | |
| SCHEMBL5017199 | 0.82 | PPARD (0.53) | PTPN1PPARDFFAR1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644368-B1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-7235572-B2 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20050004187-A1 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004187-A1 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | PTPN1 1169/4885PPARD 1/4885FFAR1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.